Business
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n  Achieves analytical performance for detecting active 3C-protease in a rapid visual format Initiates multicenter clinical trial at Assuta Ashdod Hospital and Tel Aviv University in Israel Technology opens potential for self-administered tests at home, school, work and airports NEW YORK, NY REHOVOT, Israel, and SINGAPORE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced positive proof-of-concept data for its proprietary 10-minute rapid point-of-care saliva-based test for detecting active SARS-CoV-2 infections. Based on these data, the Company has initiated a multicenter clinical trial at Assuta Ashdod Hospital and Tel Aviv University in Israel to evaluate the clinical performance of the assay, and optimize product development prototypes for commercial scale-up. This technology holds promise to provide a rapid result without the need for heating, expensive instrumentation, inconvenient sample collection or cold-chain logistics. As such, it may have applicability for self-testing at home, or where large numbers of people gather such as school, work, airports, etc.  Todos envisions developing both quantitative and qualitative tests based on the technology and intellectual property.  The Company is working to complete this initial clinical trial in the third quarter of 2020, with trial results and submissions to regulatory agencies worldwide in the fourth quarter of 2020. “These data provide proof-of-concept for the 3C-Protease diagnostic approach in COVID-19 testing,” said Dr. Jorge Leon, consulting Chief Medical & Scientific Officer of Oncology and Infectious Disease for Todos. “The clinical trial in Israel will generate real-world data on how best to integrate this technology platform into products that can be deployed worldwide. We will now begin incorporating the software to analyze this assay into an application for use with mobile phones and various telemedicine platforms, so as to provide a more complete and efficient solution for COVID-19 testing and data reporting for all stakeholders.” The pr...